Literature DB >> 20153282

Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease.

Raphaël M Zellweger1, Tyler R Prestwood, Sujan Shresta.   

Abstract

Dengue virus (DENV) causes disease ranging from dengue fever (DF), a self-limited febrile illness, to the potentially lethal dengue hemorrhagic fever and dengue shock syndrome (DHF/DSS). DHF/DSS usually occurs in patients who have acquired DENV-reactive antibodies prior to infection, either from a previous infection with a heterologous DENV serotype or from an immune mother. Hence, it has been hypothesized that subneutralizing levels of antibodies exacerbate disease, a phenomenon termed antibody-dependent enhancement (ADE). However, given the lack of suitable animal models for DENV infection, the mechanism of ADE and its contribution to pathology remain elusive. Here we demonstrate in mice that DENV-specific antibodies can sufficiently increase severity of disease so that a mostly nonlethal illness becomes a fatal disease resembling human DHF/DSS. Antibodies promote massive infection of liver sinusoidal endothelial cells (LSECs), resulting in increased systemic levels of virus. Thus, a subprotective humoral response may, under some circumstances, have pathological consequences. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20153282      PMCID: PMC2824513          DOI: 10.1016/j.chom.2010.01.004

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  39 in total

1.  Infection of human cells by dengue virus is modulated by different cell types and viral strains.

Authors:  M S Diamond; D Edgil; T G Roberts; B Lu; E Harris
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 2.  Antibodies, viruses and vaccines.

Authors:  Dennis R Burton
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

3.  Single amino acid substitution in the V protein of simian virus 5 differentiates its ability to block interferon signaling in human and murine cells.

Authors:  D F Young; N Chatziandreou; B He; S Goodbourn; R A Lamb; R E Randall
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

4.  Detection of dengue virus RNA by reverse transcription-polymerase chain reaction in the liver and lymphoid organs but not in the brain in fatal human infection.

Authors:  L Rosen; M T Drouet; V Deubel
Journal:  Am J Trop Med Hyg       Date:  1999-11       Impact factor: 2.345

Review 5.  Cytokine cascade in dengue hemorrhagic fever: implications for pathogenesis.

Authors:  U C Chaturvedi; R Agarwal; E A Elbishbishi; A S Mustafa
Journal:  FEMS Immunol Med Microbiol       Date:  2000-07

Review 6.  Immunology and immunopathogenesis of dengue disease.

Authors:  Alan L Rothman
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

7.  Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining.

Authors:  Scott J Balsitis; Josefina Coloma; Glenda Castro; Aracely Alava; Diana Flores; James H McKerrow; P Robert Beatty; Eva Harris
Journal:  Am J Trop Med Hyg       Date:  2009-03       Impact factor: 2.345

8.  Inhibition of interferon signaling by dengue virus.

Authors:  Jorge L Muñoz-Jordan; Gilma G Sánchez-Burgos; Maudry Laurent-Rolle; Adolfo García-Sastre
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-11       Impact factor: 11.205

9.  DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells.

Authors:  Boonrat Tassaneetrithep; Timothy H Burgess; Angela Granelli-Piperno; Christine Trumpfheller; Jennifer Finke; Wellington Sun; Michael A Eller; Kovit Pattanapanyasat; Suttipant Sarasombath; Deborah L Birx; Ralph M Steinman; Sarah Schlesinger; Mary A Marovich
Journal:  J Exp Med       Date:  2003-04-07       Impact factor: 14.307

10.  A dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN)-related protein is highly expressed on human liver sinusoidal endothelial cells and promotes HIV-1 infection.

Authors:  A A Bashirova; T B Geijtenbeek; G C van Duijnhoven; S J van Vliet; J B Eilering; M P Martin; L Wu; T D Martin; N Viebig; P A Knolle; V N KewalRamani; Y van Kooyk; M Carrington
Journal:  J Exp Med       Date:  2001-03-19       Impact factor: 14.307

View more
  172 in total

1.  A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease.

Authors:  Vanessa V Sarathy; Mellodee White; Li Li; Summer R Gorder; Richard B Pyles; Gerald A Campbell; Gregg N Milligan; Nigel Bourne; Alan D T Barrett
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells.

Authors:  Simona Zompi; Brian H Santich; P Robert Beatty; Eva Harris
Journal:  J Immunol       Date:  2011-11-30       Impact factor: 5.422

Review 3.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.

Authors:  Aravinda M de Silva; Eva Harris
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

4.  CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination.

Authors:  Lauren E Yauch; Tyler R Prestwood; Monica M May; Malika M Morar; Raphaël M Zellweger; Bjoern Peters; Alessandro Sette; Sujan Shresta
Journal:  J Immunol       Date:  2010-09-24       Impact factor: 5.422

Review 5.  Barriers to preclinical investigations of anti-dengue immunity and dengue pathogenesis.

Authors:  Ashley L St John; Soman N Abraham; Duane J Gubler
Journal:  Nat Rev Microbiol       Date:  2013-05-08       Impact factor: 60.633

6.  Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus.

Authors:  James D Brien; Soila Sukupolvi-Petty; Katherine L Williams; Chia-Ying Kao Lam; Michael A Schmid; Syd Johnson; Eva Harris; Michael S Diamond
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

7.  The roles of IRF-3 and IRF-7 in innate antiviral immunity against dengue virus.

Authors:  Hui-Wen Chen; Kevin King; Jui Tu; Marisa Sanchez; Andrew D Luster; Sujan Shresta
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

8.  Synergism between the tyrosine kinase inhibitor sunitinib and Anti-TNF antibody protects against lethal dengue infection.

Authors:  Emilie Branche; William Weihao Tang; Karla M Viramontes; Matthew Perry Young; Nicholas Sheets; Yunichel Joo; Anh-Viet T Nguyen; Sujan Shresta
Journal:  Antiviral Res       Date:  2018-07-30       Impact factor: 5.970

9.  Dengue Virus Evolution under a Host-Targeted Antiviral.

Authors:  Emily Plummer; Michael D Buck; Marisa Sanchez; Jason A Greenbaum; Julia Turner; Rajvir Grewal; Brennan Klose; Aruna Sampath; Kelly L Warfield; Bjoern Peters; Urban Ramstedt; Sujan Shresta
Journal:  J Virol       Date:  2015-03-11       Impact factor: 5.103

10.  Dengue reporter viruses reveal viral dynamics in interferon receptor-deficient mice and sensitivity to interferon effectors in vitro.

Authors:  John W Schoggins; Marcus Dorner; Michael Feulner; Naoko Imanaka; Mary Y Murphy; Alexander Ploss; Charles M Rice
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.